A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone(TM) (atovaquone/proguanil) for the prophylaxis of malaria in Zambia

American Journal of Tropical Medicine and Hygiene

Volumn 60, Issue 4, 1999, Pages 521-525

  Sukwa, T Y ^a   Mulenga, M ^a   Chisdaka, N ^a   Roskell, N S ^b   Scott, T R ^b  

^a Tropical Diseases Research Centre Ndola   (Zambia)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD SMEAR; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; ZAMBIA;

EID: 0032955460     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.60.521     Document Type: Article

References (25)

1. Olliaro P, Cattani J, Wirth D, 1996. Malaria, the submerged disease. JAMA 275: 230-233.
2. World Health Organization, 1990. Practical chemotherapy of malaria. World Health Organ Tech Rep Ser 805: 1-141.
3. Anonymous, 1992. Towards a malarial vaccine (editorial). Lancet 339: 586-587.
4. Hoffman SL, 1992. Diagnosis, treatment, and prevention of malaria. Med Clin North Am 76: 1327-1355.
5. Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL, 1995. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline and chloroquine plus proguanil. J Infect Dis 171: 1569-1575.
6. Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo, Richie TL, Ohrt CK, Mouzin E, Church CJ, Richards AL, Subianto B, Sandjaja B, Wignall FS, Hoffman SL, 1995. Randomized placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 346: 1190-1193.
7. Fry M, Pudney M, 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43: 1545-1553.
8. Hammond DJ, Burchell JR, Pudney M, 1985. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol 14: 97-109.
9. Srivastava IK, Rottenberg H, Vaidya AB, 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 272: 3961-3966.
10. Anonymous, 1991. Proguanil (hydrochloride). Dollery C, ed. Therapeutic Drugs. Volume 2. London: Churchill Livingstone, 247-251.
11. Canfield CJ, Boudreau EF, Altstatt LB, Dausel LL, Hutchinson DB, 1995. Worldwide controlled clinical trials with atovaquone and proguanil for treatment of Plasmodium falciparum malaria. Am J Trop Med Hyg 53 (suppl): 87 (abstract).
12. Blanchard TJ, Mabey DC, Hunt-Cooke A, Edwards G, Hutchinson DB, Benjamin S, Chiodini PL, 1994. Multiresistant falciparum malaria cured using atovaquone and proguanil. Trans R Soc Trop Med Hyg 88: 693.
13. Radloff PD, Phillips J, Nkeyi M, Hutchinson D, Kremsner PG, 1996. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 347: 1511-1514.
14. de Alencar FEC, Cerutti Jr C, Durlacher RR, Boulos M, Alves FP, Milhous W, Pang LW, 1997. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 175: 1544-1547.
15. Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, Scott TR, 1998. Efficacy and safety of atovaquone/ proguanil for suppressive prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 27: 494-499.
16. Lell B, Luckner D, Ndjavé M, Scott T, Kremsner PG, 1998. A randomised, placebo-controlled, double-blind study of atovaquone and proguanil for malaria chemoprophylaxis. Lancet 351: 709-713.
17. Rolan PE, Mercer AJ, Weatherly BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J, 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 37: 13-20.
18. Hollander M, Wolfe DA, 1973. Nonparametric Statistical Methods. New York: Wiley, 67-69.
19. Canfield CJ, Pudney M, Gutteridge WE, 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80: 373-381.
20. Haile LG, Flaherty JF, 1993. Atovaquone: a review. Ann Pharmacother 27: 1488-1494.
21. Torres RA, Weinberg W, Stansell J, Leoung G, Kovacs J, Rogers M, Scott J, 1997. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 24: 422-429.
22. Eriksson B, Björkman A, Keisu M, 1991. How safe is proguanil: a post-marketing investigation of side-effects. Scand J Infect Dis 23: 489-493.
23. McGregor IA, 1987. Malarial immunity: current trends and prospects. Ann Trop Med Parasitol 81: 647-656.
24. White NJ, 1993. The development of immunity to malaria (a clinical view) (editorial). Asian Pacific J Allergy Immunol 11: 1-3.
25. Hoffman SL, Oster CN, Plowe CV, Woollett GR, Beier JC, Chulay JD, Wirtz RA, Hollingdale MR, Mugambi M, 1987. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 237: 639-642.